UNSPSC 51432901: Belfosdil

This classification denotes a calcium channel blocker with the molecular formula C27H50O7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W91CMS1V7Z, chemically known as phosphonic acid, (2-(2-phenoxyethyl)-1,3-propanediyl)bis-, tetrabutyl ester but generally known as belfosdil, which bears US NIH Compound Identifier 72122. European Medicines Agency schedules Belfosdil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05687MIG.

UNSPSC 51432901 Belfosdil, a Commodity code, encompasses pharmaceutical products procured by state and local health agencies and public safety departments. State and local governments buy this code when sourcing specific medications for emergency medical services, public health programs, and institutional healthcare delivery — grounded in recent solicitations that specify individual medication line items with precise unit counts, expiration requirements, and delivery timelines. The issuing bodies include municipal fire and emergency services departments (exemplified by Tampa Fire Rescue), state health and human services agencies managing pharmacy benefit programs, and cooperative purchasing alliances serving multi-state networks of government facilities. These buyers source medications through sealed-bid procurements, requests for information to evaluate vendor capabilities, and cooperative purchasing agreements that establish standing contracts with multiple authorized wholesalers.

Activity appears concentrated in Florida and Texas, with multi-state procurement infrastructure in Minnesota. The City of Tampa's Purchasing Department posted an IFB (Bid No. 26-P-00188) on April 24, 2026 for Advanced Life Support Medications — Labetalol, Epinephrine, Adenosine, and Diltiazem — due April 8, 2026, with an estimated contract value of $40,000 and a one-year initial term plus renewal options; the solicitation carried a 5 percent bid discount for Small Local Business Enterprises not to exceed $10,000. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) on April 3, 2026 exploring direct-to-manufacturer prescription fulfillment strategies outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring vendors to supply through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson) with contract effectiveness July 1, 2026; evaluation weighted price competitiveness at 75 percent and required cGMP certification and Drug Supply Chain Security Act compliance.